New insider activity at Thermo Fisher ( (TMO) ) has taken place on September 2, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph R. Holmes, the Vice President and Chief Accounting Officer of Thermo Fisher, has recently sold 385 shares of the company’s stock. This transaction was valued at $189,660.
Recent Updates on TMO stock
In the latest developments surrounding Thermo Fisher, William Blair initiated coverage with an Outperform rating, highlighting the company’s ‘one-stop-shop’ pharma partnership strategy as a key driver for potential multiple expansion. This strategy positions Thermo Fisher as a preferred partner in the biopharma industry, which, despite constraining shares in the short term, is expected to be a resilient and attractive market in the long run. Additionally, Thermo Fisher recently received FDA approval for its Oncomine Dx product, further strengthening its market position and growth prospects. These strategic initiatives and positive market outlook have contributed to the favorable ratings and expectations for the company’s stock performance.
Spark’s Take on TMO Stock
According to Spark, TipRanks’ AI Analyst, TMO is a Outperform.
Thermo Fisher’s strong financial performance and positive earnings call guidance are the most significant factors driving the stock score. The technical analysis supports a bullish outlook, though the high valuation and challenges in certain markets temper the overall score. The recent acquisition adds strategic value but has a short-term dilutive effect.
To see Spark’s full report on TMO stock, click here.
More about Thermo Fisher
YTD Price Performance: -5.11%
Average Trading Volume: 2,638,100
Technical Sentiment Signal: Buy
Current Market Cap: $186.1B